Exact Mass: 656.4333
Exact Mass Matches: 656.4333
Found 88 metabolites which its exact mass value is equals to given mass value 656.4333,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Enalkiren
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
PA(15:0/18:3(6Z,9Z,12Z))
PA(15:0/18:3(6Z,9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(15:0/18:3(6Z,9Z,12Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of gamma-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(15:0/18:3(9Z,12Z,15Z))
PA(15:0/18:3(9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(15:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of alpha-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:3(6Z,9Z,12Z)/15:0)
PA(18:3(6Z,9Z,12Z)/15:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(6Z,9Z,12Z)/15:0), in particular, consists of one chain of gamma-linolenic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:3(9Z,12Z,15Z)/15:0)
PA(18:3(9Z,12Z,15Z)/15:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(9Z,12Z,15Z)/15:0), in particular, consists of one chain of alpha-linolenic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
Enalkiren
[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (Z)-heptadec-9-enoate
[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropyl] heptadecanoate
[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[(Z)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[(2R)-1-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate
[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,12E)-octadeca-9,12-dienoate
[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate
2-[[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,11E)-octadeca-9,11-dienoate
[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (6E,9E)-octadeca-6,9-dienoate
[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate
[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate
[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate
[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate
[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] heptadecanoate
[(2R)-1-pentadecanoyloxy-3-phosphonooxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-phosphonooxypropyl] (9E,12E)-heptadeca-9,12-dienoate
[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropyl] (9E,12E)-heptadeca-9,12-dienoate
[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (E)-heptadec-7-enoate
[(2R)-2-pentadecanoyloxy-3-phosphonooxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate
[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate
[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate
2-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate
[(2R)-1-[(E)-hexadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate
2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-propanoyloxy-2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-nonanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-heptanoyloxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-pentanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
SLIGRL-NH2
SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) is an agonist of Protease-Activated Receptor-2 (PAR-2)[1].
